Background Compulsory urine testing of prisoners for drugs, a control
initiative, was introduced in eight prisons in England and Wales early
in 1995, Despite no evidence of effectiveness, testing was extended t
o all prisons in England and Wales by March 1996. We consider the cost
of testing. Methods We combined the costs of refusals, confirmatory t
ests, punishment of confirmed positives for cannabis or for class A dr
ugs to estimate the average costs of random compulsory drugs testing.
These costs were then compared to: i) the healthcare budget for a pris
on; and ii) the cost of putting in place a credible prisons' drugs red
uction programme. We then used Scottish data on incarceration and regi
onal prevalence of injecting drug users to estimate the extent of the
injecting drug use problem that prisons face. Findings Costs per 28 da
ys of the random mandatory drugs testing control initiative in an esta
blishment for 500 inmates where refusal rate is a) 10% or b) nil; and
35% of urine samples test positive, one tenth of them for class A drug
s were estimated at between a) pound UK22 800 and b) pound UK16 000 pe
r 28 days [a) $US35 100 and b) $US24 600]. This cost was equivalent to
twice the cost of running a credible drugs reduction and rehabilitati
on programme, and around half the total healthcare expenditure for a p
rison of 500 which averaged pound UK41 114 per 28 days [$US64 860]. Ma
jor cost-generating events were the punishment of refusals-over one th
ird of cost a)-and testing positive for cannabis-over 50% of cost a).
In Scotland, around 5% of injecting drug users (IDUs) are incarcerated
at any time: 5% of Lothian's drugs care, treatment and prevention cos
ts and 2 . 5% of its HIV/AIDS prevention budget in 1993-94 amounted to
pound EUK101 300 per annum-or pound UK7770 per 28 days ($US11 970)-an
d about 35% of monthly MDT costs. Interpretation We suggest that 5% of
current resources for drugs prevention and treatment and for IDU-targ
etted HIV/AIDS prevention should be directed towards the prisons becau
se in the prisons, where 5% of the clients are at any time. injectors
have less access to harm reduction measures than on the outside.